MENLO PARK, Calif.--(BUSINESS WIRE)--
Intersect ENT, Inc. (NASDAQ:XENT) announced the publication of a position statement from the American Rhinologic Society (ARS) endorsing the utilization of drug eluting sinus implants.
The ARS position statement cites the volume of well-controlled studies supporting the use of implants that release steroids to the local tissues and highlights the importance of reducing polyp burden and inflammation, which can result in a decrease in the use of oral medications as well as delaying the time to revision surgery. The society also strongly states its position that drug eluting implants are not investigational and should be made available to patients, when selected by the physician, in order to maximize outcomes.
“We are pleased that the ARS has issued this clear statement for its members endorsing the use of drug eluting sinus implants,” said Lisa Earnhardt, president and CEO, Intersect ENT. “Our PROPEL® steroid releasing implants, the first and only FDA-approved products of their kind, have been proven to deliver improved outcomes clinically and economically. To date, more than 100,000 patients have been treated with PROPEL and we will continue to work diligently with payers and providers to ensure patients and physicians have access to this technology. In addition, we look forward to continuing to provide innovative solutions for the ENT specialty.”
About PROPEL and PROPEL mini
Intersect ENT’s PROPEL and PROPEL mini are the first and only steroid releasing sinus implants approved by the FDA to maintain the open passages created in surgery. The bioabsorbable products release mometasone furoate, an advanced steroid with anti-inflammatory properties, over time directly into the sinus lining, then fully dissolve. PROPEL’s effectiveness is supported by the highest level of clinical evidence, Level 1a, which demonstrates that PROPEL reduces inflammation and scarring after surgery thereby lessening the need for post-operative surgical interventions and use of oral steroids. Both PROPEL and PROPEL mini are indicated for use following ethmoid sinus surgery. Additionally, PROPEL mini is indicated for use following frontal sinus surgery.
About Intersect ENT
Intersect ENT, Inc. is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The company markets two steroid releasing implants, PROPEL and PROPEL mini, which have been clinically proven to improve surgical outcomes for chronic sinusitis patients undergoing sinus surgery. In addition, Intersect ENT is developing a pipeline of steroid releasing implants designed to provide ENT physicians with options to treat patients across the continuum of care for chronic sinusitis less invasively and more cost effectively. Chronic sinusitis is an inflammatory condition that can lead to debilitating symptoms and chronic infections, and is one of the most costly conditions to U.S. employers.
For additional information on the company or the products including risks and benefits please visit www.intersectENT.com.
INTERSECT ENT® and PROPEL® are registered trademarks of Intersect ENT, Inc.
XENT-G
View source version on businesswire.com: http://www.businesswire.com/news/home/20160919005457/en/
